March 8, 2024 02:53 PM ESTUpdated 05:28 PM

Akero executives point to advanced fibrosis patients for MASH drug

Katherine Lewin

News Reporter

Akero Therapeutics expects its promising experimental MASH drug will be used to treat patients with advanced fibrosis if it receives FDA approval, likening MASH to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Akero executives point to advanced fibrosis patients for MASH drug

Katherine Lewin

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Akero ex­ec­u­tives point to ad­vanced fi­bro­sis pa­tients for MASH drug

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Akero executives point to advanced fibrosis patients for MASH drug